# reload+after+2024-01-20 13:43:37.684513
address1§238 Main Street
address2§9th Floor
city§Cambridge
state§MA
zip§02142-1016
country§United States
phone§857 327 8775
website§https://beamtx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 and BEAM-102 for the treatment of sickle cell disease beta thalassemia; BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease; and the Institute of Molecular and Clinical Ophthalmology Basel for treatment of impaired vision and blindness. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.
fullTimeEmployees§439
companyOfficers§[{'maxAge': 1, 'name': 'Mr. John M. Evans M.B.A.', 'age': 45, 'title': 'CEO & Director', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 1110320, 'exercisedValue': 9033400, 'unexercisedValue': 19970976}, {'maxAge': 1, 'name': 'Dr. Giuseppe  Ciaramella Ph.D.', 'age': 54, 'title': 'President', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 933195, 'exercisedValue': 1271442, 'unexercisedValue': 20026302}, {'maxAge': 1, 'name': 'Ms. Terry-Ann  Burrell M.B.A.', 'age': 46, 'title': 'CFO & Treasurer', 'yearBorn': 1977, 'fiscalYear': 2022, 'totalPay': 711150, 'exercisedValue': 0, 'unexercisedValue': 5541172}, {'maxAge': 1, 'name': 'Dr. Feng  Zhang Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David R. Liu Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. J. Keith Joung M.D., Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nicole  Gaudelli Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Alexis  Komor Ph.D.', 'title': 'Co-Founder', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Manmohan  Singh Ph.D.', 'title': 'Chief Technology Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Gopi  Shanker Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§8
boardRisk§9
compensationRisk§8
shareHolderRightsRisk§5
overallRisk§8
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§1.66
priceToSalesTrailing12Months§26.054047
currency§USD
dateShortInterest§1702598400
forwardEps§-4.62
pegRatio§-1.43
exchange§NMS
quoteType§EQUITY
shortName§Beam Therapeutics Inc.
longName§Beam Therapeutics Inc.
firstTradeDateEpochUtc§1580999400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§59de9e0e-05e5-3c20-a484-b2350c3fa77a
gmtOffSetMilliseconds§-18000000
targetHighPrice§95.0
targetLowPrice§19.0
targetMeanPrice§47.62
targetMedianPrice§38.0
recommendationMean§2.2
recommendationKey§buy
numberOfAnalystOpinions§13
quickRatio§4.608
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
